Pharmaceutical Technology

OCTOBER 28, 2022

What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20. The company says that these four serotypes represent roughly 10–15% of bacteria causing pneumococcal disease in adults. VAX-24 has forecasted sales of $21 million in the same year. billion and $812 million in 2028.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

pharmaphorum

DECEMBER 4, 2020

Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

XTalks

JUNE 21, 2024

According to a November 2023 readout, Capvaxive also elicited superior immune responses for ten of the 11 serotypes not covered by Prevnar 20. In 2023, Vaxneuvance, which was approved in 2021, netted $665 million in sales. Last year, sales of Pfizer’s pneumococcal vaccines reached $6.4

FDA Approval 108

FDA Approval Vaccination Vaccine Life Science 108

pharmaphorum

MAY 31, 2022

Last year, Affinivax reported positive phase 2 results with ASP3772, which targets 24 of the common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. billion in sales last year.

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

pharmaphorum

JULY 14, 2021

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccine Vaccination Protein 52

The Pharma Data

JUNE 30, 2021

Yasmin Parr’s study of FeLV shows that the outcome of FeLV infection is influenced by the host immune response, with progressively infected cats, so cats whose conditions are worsening, having weaker immune responses. “In billion euros in 2020 and presence in more than 150 countries.

Scientist 52

Scientist Immune Response Antibody Development 52